WebJun 6, 2024 · NEW YORK (GenomeWeb) – A multi-basket trial launched by the American Society of Clinical Oncology three years ago has reported out the first positive data from two arms demonstrating activity for Pfizer's palbociclib (Ibrance) and Merck's pembrolizumab (Keytruda) in biomarker-defined cancers. WebThe Targeted Agent and Profiling Utilization Registry (TAPUR) Study is a non-randomized clinical trial that aims to describe the safety and efficacy of commercially available, targeted anticancer drugs prescribed for treatment of patients with advanced cancer that has a potentially actionable genomic variant.
Pembrolizumab in Patients With Metastatic Breast Cancer With ... - PubMed
WebBackground Information. The Targeted Agent and Profiling Utilization Registry (TAPUR) Study is a non-randomized clinical trial that aims to describe the performance (both safety and efficacy) of commercially available, targeted anticancer drugs prescribed for treatment of patients with advanced cancer that has a potentially actionable genomic ... WebAug 21, 2015 · The prospective, nonrandomized TAPUR clinical trial will collect information on the antitumor activity and toxicity of commercially available targeted cancer drugs in a range of cancer types (including advanced solid tumors, multiple myeloma, and B-cell non-Hodgkin lymphoma) with a genomic variation known to be a drug target. scs66str
Trastuzmab Plus Pertuzumab Targets ERBB2/ERBB3 in Uterine …
WebASCO’s Targeted Agent and Profiling Utilization Registry (TAPUR) Study is a non-randomized clinical trial aiming to describe the performance of commercially available, targeted anticancer drugs prescribed for treatment of patients with advanced cancer with a potentially actionable genomic variant. Visit Site WebJun 7, 2024 · In this arm of the TAPUR trial, investigators evaluated the combination of pertuzumab and trastuzumab in 28 patients with ERBB2/ERBB3-positive uterine cancer. To be eligible for enrollment on this cohort, patients needed to have advanced uterine cancer with an ECOG performance status of 0 to 2, adequate organ function, measurable disease, … WebMar 2, 2024 · So far, Pfizer has partnered with Strata to provide drugs to advanced solid tumor patients in four arms of the platform trial, dubbed Strata Precision Indications for Approved Therapies, or Strata PATH. ... The American Society of Clinical Oncology's TAPUR trial is one such effort and has reported out several positive arms. sc s.613